Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development

…, J O'shaughnessy, KZ Guyton, DA Mankoff… - Clinical Cancer …, 2005 - AACR
2-[ 18 F]Fluoro-2-deoxyglucose positron emission tomography (FDG-PET) assesses a
fundamental property of neoplasia, the Warburg effect. This molecular imaging technique offers a …

[HTML][HTML] Hyperpolarized 13C MRI: path to clinical translation in oncology

…, KR Keshari, A Kjaer, C Laustsen, DA Mankoff… - Neoplasia, 2019 - Elsevier
This white paper discusses prospects for advancing hyperpolarization technology to better
understand cancer metabolism, identify current obstacles to HP (hyperpolarized) 13 C …

ACR appropriateness criteria breast cancer screening

…, PM Jokich, SJ Lee, CD Lehman, DA Mankoff… - Journal of the American …, 2016 - Elsevier
Mammography is the recommended method for breast cancer screening of women in the
general population. However, mammography alone does not perform as well as …

Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials

…, AA Lammertsma, S Larson, DA Mankoff… - Journal of Nuclear …, 2006 - Soc Nuclear Med
Despite the increasing use of 18F-FDG PET as a biomarker for predicting therapeutic response,
there are no widely accepted standardized protocols for using 18F-FDG PET as a tool …

A definition of molecular imaging

DA Mankoff - The Journal of Nuclear Medicine, 2007 - search.proquest.com
To assist with the understanding of molecular imaging in clinical care, statements were
developed that can be used to help communicate the importance of molecular imaging:* …

Phase II study of daily sunitinib in FDG-PET–positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional …

LL Carr, DA Mankoff, BH Goulart, KD Eaton… - Clinical Cancer …, 2010 - AACR
Purpose: We conducted a phase II study to assess the efficacy of continuous dosing of
sunitinib in patients with flurodeoxyglucose positron emission tomography (FDG-PET)–avid, …

Hypoxia and Glucose Metabolism in Malignant Tumors: Evaluation by [18F]Fluoromisonidazole and [18F]Fluorodeoxyglucose Positron Emission Tomography …

JG Rajendran, DA Mankoff, F O'Sullivan… - Clinical cancer …, 2004 - AACR
Purpose: The aim of this study is to compare glucose metabolism and hypoxia in four different
tumor types using positron emission tomography (PET). F-labeled fluorodeoxyglucose (…

[PDF][PDF] Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer

…, EK Schubert, LK Dunnwald, KA Krohn, DA Mankoff - J Clin Oncol, 2006 - academia.edu
Purpose In breast cancer,[18F] fluoroestradiol (FES) positron emission tomography (PET)
correlates with estrogen receptors (ER) expression and predicts response to tamoxifen. We …

Imaging P‐glycoprotein transport activity at the human blood‐brain barrier with positron emission tomography

…, JM Link, M Muzi, DA Mankoff… - Clinical …, 2005 - Wiley Online Library
Background Numerous knockout mouse studies have revealed that P‐glycoprotein (P‐gp)
significantly limits drug distribution across the mouse blood‐brain barrier (BBB). To determine …

Application of photoshop-based image analysis to quantification of hormone receptor expression in breast cancer

HA Lehr, DA Mankoff, D Corwin… - … of Histochemistry & …, 1997 - journals.sagepub.com
The benefit of quantifying estrogen receptor (ER) and progesterone receptor (PR) expression
in breast cancer is well established. However, in routine breast cancer diagnosis, receptor …